Inhibikase
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Inhibikase and other ETFs, options, and stocks.About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases.
CEOMark T. Iwicki
CEOMark T. Iwicki
Employees35
Employees35
HeadquartersWilmington, Delaware
HeadquartersWilmington, Delaware
Founded2008
Founded2008
Employees35
Employees35
IKT Key Statistics
Market cap332.79M
Market cap332.79M
Price-Earnings ratio-5.48
Price-Earnings ratio-5.48
Dividend yield—
Dividend yield—
Average volume560.87K
Average volume560.87K
High today$2.42
High today$2.42
Low today$2.32
Low today$2.32
Open price$2.41
Open price$2.41
Volume486.63K
Volume486.63K
52 Week high$2.53
52 Week high$2.53
52 Week low$1.33
52 Week low$1.33
Stock Snapshot
As of today, Inhibikase(IKT) shares are valued at $2.39. The company's market cap stands at 332.79M, with a P/E ratio of -5.48.
On 2026-08-17, Inhibikase(IKT) stock traded between a low of $2.32 and a high of $2.42. Shares are currently priced at $2.39, which is +3.0% above the low and -1.0% below the high.
The Inhibikase(IKT)'s current trading volume is 486.63K, compared to an average daily volume of 560.87K.
During the past year, Inhibikase(IKT) stock moved between $1.33 at its lowest and $2.53 at its peak.
During the past year, Inhibikase(IKT) stock moved between $1.33 at its lowest and $2.53 at its peak.
Analyst ratings
100%
of 9 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IKT. This list is generated using Robinhood data, and it’s not a recommendation.